John P. Sheehan

Array ( [id] => 7696685 [patent_doc_number] => 20110229905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RLATED TO BECLIN-1' [patent_app_type] => utility [patent_app_number] => 13/132589 [patent_app_country] => US [patent_app_date] => 2009-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17723 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0229/20110229905.pdf [firstpage_image] =>[orig_patent_app_number] => 13132589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6431204 [patent_doc_number] => 20100152114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-17 [patent_title] => 'Antioxidant activity of GH-RH Antagonists' [patent_app_type] => utility [patent_app_number] => 12/626913 [patent_app_country] => US [patent_app_date] => 2009-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4400 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0152/20100152114.pdf [firstpage_image] =>[orig_patent_app_number] => 12626913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6245644 [patent_doc_number] => 20100136004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-03 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS' [patent_app_type] => utility [patent_app_number] => 12/624035 [patent_app_country] => US [patent_app_date] => 2009-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15841 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0136/20100136004.pdf [firstpage_image] =>[orig_patent_app_number] => 12624035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6436528 [patent_doc_number] => 20100143924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-10 [patent_title] => 'NEGATIVE CORRELATION BETWEEN IRP-2 AND TRANSFERRIN RECEPTOR EXPRESSION AS A DIAGNOSTIC OF ALZHEIMER\'S DISEASE' [patent_app_type] => utility [patent_app_number] => 12/621411 [patent_app_country] => US [patent_app_date] => 2009-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 40932 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0143/20100143924.pdf [firstpage_image] =>[orig_patent_app_number] => 12621411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6247456 [patent_doc_number] => 20100136700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-03 [patent_title] => 'METABOLIC SYNDROME AND HPA AXIS BIOMARKERS FOR MAJOR DEPRESSIVE DISORDER' [patent_app_type] => utility [patent_app_number] => 12/620831 [patent_app_country] => US [patent_app_date] => 2009-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8576 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0136/20100136700.pdf [firstpage_image] =>[orig_patent_app_number] => 12620831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9455212 [patent_doc_number] => 08716220 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-06 [patent_title] => 'Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta' [patent_app_type] => utility [patent_app_number] => 12/612613 [patent_app_country] => US [patent_app_date] => 2009-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 47915 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12612613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6080104 [patent_doc_number] => 20110142841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'Compositions and methods for the treatment of systemic lupus erythematosis' [patent_app_type] => utility [patent_app_number] => 12/589398 [patent_app_country] => US [patent_app_date] => 2009-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 662 [patent_figures_cnt] => 662 [patent_no_of_words] => 38461 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12589398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6574352 [patent_doc_number] => 20100129348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-27 [patent_title] => 'METHOD FOR DECREASING DEPRESSION BY INHIBITING THE ACTIVITY OF ALPHA 1B SUBUNIT OF N-TYPE CALCIUM CHANNEL' [patent_app_type] => utility [patent_app_number] => 12/580372 [patent_app_country] => US [patent_app_date] => 2009-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6631 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20100129348.pdf [firstpage_image] =>[orig_patent_app_number] => 12580372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6624305 [patent_doc_number] => 20100100333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'HUMAN BIOMARKER HYPERMAPPING FOR DEPRESSIVE DISORDERS' [patent_app_type] => utility [patent_app_number] => 12/579733 [patent_app_country] => US [patent_app_date] => 2009-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5512 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0100/20100100333.pdf [firstpage_image] =>[orig_patent_app_number] => 12579733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7561733 [patent_doc_number] => 20110275566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'METHODS OF TREATING NECROTIZING ENTEROCOLITIS USING HEPARIN BINDING EPIDERMAL GROWTH FACTOR (HB-EGF)' [patent_app_type] => utility [patent_app_number] => 13/123420 [patent_app_country] => US [patent_app_date] => 2009-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11881 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20110275566.pdf [firstpage_image] =>[orig_patent_app_number] => 13123420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5959522 [patent_doc_number] => 20110183909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-28 [patent_title] => 'Treatment of Mood and Anxiety Disorders' [patent_app_type] => utility [patent_app_number] => 13/121804 [patent_app_country] => US [patent_app_date] => 2009-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 9756 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20110183909.pdf [firstpage_image] =>[orig_patent_app_number] => 13121804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6500295 [patent_doc_number] => 20100286248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'HUMAN FG01 GENE AND ITS APPLICATIONS' [patent_app_type] => utility [patent_app_number] => 12/566951 [patent_app_country] => US [patent_app_date] => 2009-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 2766 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0286/20100286248.pdf [firstpage_image] =>[orig_patent_app_number] => 12566951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6492496 [patent_doc_number] => 20100209346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-19 [patent_title] => 'AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/559255 [patent_app_country] => US [patent_app_date] => 2009-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 29277 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0209/20100209346.pdf [firstpage_image] =>[orig_patent_app_number] => 12559255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5464292 [patent_doc_number] => 20090324492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-31 [patent_title] => 'Treatment for Central Nervous System Disorders' [patent_app_type] => utility [patent_app_number] => 12/550944 [patent_app_country] => US [patent_app_date] => 2009-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6910 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0324/20090324492.pdf [firstpage_image] =>[orig_patent_app_number] => 12550944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11282677 [patent_doc_number] => 09498515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'Compositions and methods for treatment during non-acute periods following CNS neurological injury' [patent_app_type] => utility [patent_app_number] => 13/059206 [patent_app_country] => US [patent_app_date] => 2009-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 26 [patent_no_of_words] => 15143 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13059206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5368432 [patent_doc_number] => 20090305991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => '33 Human Secreted Proteins' [patent_app_type] => utility [patent_app_number] => 12/538668 [patent_app_country] => US [patent_app_date] => 2009-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 125418 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0305/20090305991.pdf [firstpage_image] =>[orig_patent_app_number] => 12538668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9086100 [patent_doc_number] => 08557526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-15 [patent_title] => 'Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury' [patent_app_type] => utility [patent_app_number] => 12/535960 [patent_app_country] => US [patent_app_date] => 2009-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 10822 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 241 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12535960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6079933 [patent_doc_number] => 20110142795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'METHODS OF TREATING COGNITIVE IMPAIRMENT' [patent_app_type] => utility [patent_app_number] => 13/057387 [patent_app_country] => US [patent_app_date] => 2009-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 19103 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20110142795.pdf [firstpage_image] =>[orig_patent_app_number] => 13057387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8560202 [patent_doc_number] => 08334264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-12-18 [patent_title] => 'Therapeutic use of a growth factor, METRNL' [patent_app_type] => utility [patent_app_number] => 12/936501 [patent_app_country] => US [patent_app_date] => 2009-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 33698 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12936501 [rel_patent_id] =>[rel_patent_doc_number] =>)